Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma — Masatoshi Kudo (2019) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma
Shared by
Masatoshi Kudo
Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma
Editorial Material
2019
en
Authors
Masatoshi Kudo
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Preprint
2019
Objective Response by mRECIST is an Independent Prognostic Factor for overall Survival in Hepatocellular Carcinoma in SILIUS Trial
Masatoshi Kudo
,
Kazuomi Ueshima
,
Yasutaka Chiba
,
Sadahisa Ogasawara
,
Shuntaro Obi
,
Namiki Izumi
,
Hiroshi Aikata
,
Hiroaki Nagano
,
Etsuro Hatano
,
Yutaka Sasaki
,
Keisuke Hino
,
Takashi Kumada
,
Kazuhide Yamamoto
,
Yasuharu Imai
,
Shouta Iwadou
,
Chikara Ogawa
,
Takuji Okusaka
,
Fumihiko Kanai
,
Yasuaki Arai
Article
2019
Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial
Masatoshi Kudo
,
Kazuomi Ueshima
,
Yasutaka Chiba
,
Sadahisa Ogasawara
,
Shuntaro Obi
,
Namiki Izumi
,
Hiroshi Aikata
,
Hiroaki Nagano
,
Etsuro Hatano
,
Yutaka Sasaki
,
Keisuke Hino
,
Takashi Kumada
,
Kazuhide Yamamoto
,
Yasuharu Imai
,
Shouta Iwadou
,
Chikara Ogawa
,
Takuji Okusaka
,
Fumihiko Kanai
,
Yasuaki Arai
Dataset
Supplementary Material for: Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial
Masatoshi Kudo
,
Kazuomi Ueshima
,
Yasutaka Chiba
,
Sadahisa Ogasawara
,
Shuntaro Obi
,
Namiki Izumi
,
Hiroshi Aikata
,
Hiroaki Nagano
,
Etsuro Hatano
,
Yasuharu Sasaki
,
Keisuke Hino
,
Takashi Kumada
,
Kazuhiro Yamamoto
,
Yoichi Imai
,
Shouta Iwadou
,
Chikara Ogawa
,
Takuji Okusaka
,
Fumihiko Kanai
,
Yasuaki Arai
Editorial Material
2023
Objective Response to Systemic Therapy Is a Strong Predictor of Overall Survival in Patients with Unresectable Hepatocellular Carcinoma
Masatoshi Kudo
Article
2020
Objective response (OR) by mRECIST to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib in the SILIUS trial.
Masatoshi Kudo
,
Kazuomi Ueshima
,
Chikara Ogawa
,
Yasutaka Chiba
Discussion(0)
No comments yet. Be the first to comment.